NomoCan Pharmaceuticals offers first-in-kind targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably,
it introduces a highly effective monoclonal antibody (mAb) drugs for the treatment of various cancers in order to
“Bring Hope” to patients affected by this devastating disease.
Pancreatic Cancer is one of the most aggressive cancers
with a 5-year survival of 8%. NomoCan’s NMC-001 is a selective and specific monoclonal antibody that is the first in its kind to be developed for pancreatic cancer. NomoCan’s NMC-001 effectively targets cancer cells without harming normal cells and therefore will not have the side effects of non-specific chemotherapeutic agents currently in the clinic.
NMC-001 monoclonal antibody targets a specific pancreatic cancer marker and is able to selectively identify and diagnose pancreatic cancer in human. With a high affinity for its target, NMC-001 demonstrates potent anti-tumor efficiency in rodent models of pancreatic cancer.
Ehsan Sarafraz-Yazdi, Ph.D., M.P.H.
Co-Founder & Chief Executive Officer
Brad Evans, Ph.D.
Lisa Wisniewski, Ph.D.
Josef Michl, M.D.
Benjamin Mumford, M.S.
Kamyar Neshvadian, M.S., F.R.M.
Chief Financial Officer
Victor Adler, M.D., Ph.D.
Dallas Broadway, M.D.
Emil Lou, M.D., Ph.D.